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Abstract: Analysis of the human proteome has identified thousands of unique protein sequences
that contain acetylated lysine residues in vivo. These modifications regulate a variety of biological
processes and are reversed by the lysine deacetylase (KDAC) family of enzymes. Despite the
known prevalence and importance of acetylation, the details of KDAC substrate recognition are
not well understood. While several methods have been developed to monitor protein deacetylation,
none are particularly suited for identifying enzyme-substrate pairs of label-free substrates across
the entire family of lysine deacetylases. Here, we present a fluorescamine-based assay which is
more biologically relevant than existing methods and amenable to probing substrate specificity.
Using this assay, we evaluated the activity of KDAC8 and other lysine deacetylases, including a
sirtuin, for several peptides derived from known acetylated proteins. KDAC8 showed clear
preferences for some peptides over others, indicating that the residues immediately surrounding
the acetylated lysine play an important role in substrate specificity. Steady-state kinetics suggest
that the sequence surrounding the acetylated lysine affects binding affinity and catalytic rate
independently. Our results provide direct evidence that potential KDAC8 substrates previously
identified through cell based experiments can be directly deacetylated by KDAC8. Conversely, the
data from this assay did not correlate well with predictions from previous screens for KDAC8
substrates using less biologically relevant substrates and assay conditions. Combining results
from our assay with mass spectrometry-based experiments and cell-based experiments will
allow the identification of specific KDAC-substrate pairs and lead to a better understanding of the
biological consequences of these interactions.
Keywords: lysine deacetylase; substrate specificity; fluorescamine; biological relevance; peptide
substrates; deacetylation assay; sirtuins
Introduction
Analysis of mammalian proteomes has identified
thousands of unique protein sequences that contain
acetylated lysine residues in vivo.1–6 This prevalent
and reversible post-translational modification is
highly regulated and is important for a variety of
biological processes. Lysine deacetylases (KDACs,
also known as histone deacetylases, EC 3.5.1.98) are
metal-dependent enzymes that reverse this post-
translational modification, by catalyzing the hydro-
lysis of e-N-acetyllysine residues in proteins via a
conserved mechanism.7–9 Like acetylation itself, the
activity of expressed KDACs has been directly
linked to a wide variety of biological processes,
including development and growth, memory forma-
tion, and regulation of metabolism.10–13 KDAC
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activity has also been linked to numerous diseases,
in particular chronic diseases such as asthma, can-
cers, muscular disorders, and diabetes.11,14–16
Metal-dependent lysine deacetylases, class I and
class II KDACs, share a conserved reaction mecha-
nism and catalytic domain, but differ widely in their
intracellular distribution and cell-type expression pat-
terns.11,17 However, with several thousand identified
nonhistone acetylated proteins, it is highly unlikely
that localization patterns alone are sufficient for the
eleven metal-dependent KDACs (several of which are
primarily localized to the cell nucleus) and seven
NAD-dependent KDACs (class III KDACs or sirtuins)
to react only with their intended substrates. Litera-
ture evidence indicates that substrates and inhibitors
likely bind in different conformations, and product
release is likely highly influenced by small conforma-
tional changes in KDACs.18–20 Therefore, it is essen-
tial to identify the particular contacts that are most
important in determining binding, as dictated by sub-
strate sequence and structure.
Despite the known prevalence and importance of
acetylation, the details of KDAC substrate recognition
are not well understood. Only a handful of the identi-
fied acetylated proteins have been matched to a partic-
ular KDAC, and the degree to which the substrate sets
are discrete or overlapping among the KDAC isozymes
is unknown, as are the factors that allow KDACs to dis-
criminate between potential substrates.21,22 The few
studies which have definitively identified substrates of
a particular KDAC were mostly directed studies using
a cell-based approach. For example, SMC3 was found
to be a KDAC8 (also known as HDAC8)23 substrate by
inhibiting KDAC8 expression in cells and monitoring
the downstream effects specifically on SMC3 and
related pathways.24 Studies such as this one are useful
for linking KDACs to their substrates; however, they
identify only a single enzyme-substrate pair and are
limited to situations where there is already a proposed
enzyme-substrate relationship. In addition, without
supporting biochemical data, it is difficult to distin-
guish between a direct enzyme-substrate relationship
and an indirect effect. A recent development is the use
of larger-scale cell based experiments relying on pull-
down techniques and mass spectrometry in an attempt
to link particular KDACs with potential substrates,
which has led to the identification of several likely sub-
strate proteins but has not yet helped clarify the differ-
ences in specificity between lysine deacetylases.25
In addition to these cell-based methods, several
in vitro biochemical assays have been developed to
directly assess KDAC activity for particular substrates.
KDAC8, and to a lesser extent a few other class I and
some class II KDACs, have been screened using
randomized substrate libraries to determine the effect
of substrate sequence.26–32 However, all these systems
present the enzyme with the substrate sequence in an
unnatural context, either as a dye-labeled conjugate
presenting only sequence upstream of the lysine or as
a peptide attached to a surface. Although experimen-
tally convenient, these substrates likely behave sig-
nificantly differently than natural substrates. An
unbiased method for quantifying lysine deacetylase
activity relies on radioactive labeling of substrates,
but such labeling is expensive and not well suited for
many applications.33,34 HPLC quantification of
deacetylated peptides has also been reported, but
this method is cumbersome and not suited for high-
throughput applications.35 Another recent approach
relies on the measurement of acetate production, and
this method can be applied as either a stopped assay,
similar to all other deacetylase assays, or as a contin-
uous assay.36 However, this method still has limited
sensitivity to small amounts of deacetylation, is con-
siderably more complex than other methods, and
cannot be used in any system where NADH is pres-
ent (such as assays for the sirtuin family of lysine
deacetylases). An analogous coupled assay for the
sirtuins based on detecting the coupled production of
nicotinamide has also been reported, but like the ace-
tate coupled assay is relatively complex and involves
the use of several enzymes working in parallel.37,38
To date, no general purpose, relatively high-throughput
label-free assay has been reported that works with all
lysine deacetylases.
Based on these limitations, we developed an
assay which would allow us to definitively identify
substrates of a specific KDAC with adequate sensi-
tivity to detect low levels of deacetylation and with-
out requiring a fluorescent inhibitor or unnatural
modification of substrate. The assay presented here
utilizes fluorescamine, a compound originally used
to detect and quantify protein, to detect free primary
amines.39–42 This molecule is ideal for detecting
deacetylation, as it specifically reacts with the prod-
uct of the deacetylation reaction (free lysine), but
not the substrate (acetylated lysine), resulting in flu-
orescence. In fact, fluorescamine has been previously
used to quantitatively monitor the deacetylation of
N-acetylglucosamine.43,44 Based on these previous
reports, we developed a fluorescamine-based assay
to measure lysine deacetylation by KDACs, which is
comparable in sensitivity to existing assays that rely
on fluorescently-conjugated substrates and is appli-
cable to all classes of KDACs. Using this assay, we
measured KDAC8 activity against several potential
peptide substrates, demonstrating that this enzyme
does show substrate preference; however, this pref-
erence does not correlate with the results of previous
screens using unnaturally modified substrates.
Results
A more biologically relevant fluorescamine assay
To address limitations of previously developed assays
to detect deacetylation, we developed a novel assay
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using fluorescamine to detect deacetylation (Fig. 1).
This assay, described in detail in the Materials and
Methods, is based on previously described assays.44,45
Briefly, KDACs were incubated with a substrate con-
taining an acetylated lysine in a buffer that more
closely approximated intracellular conditions than
standard buffers used in deacetylase assays.46 Once
the reaction was stopped, fluorescamine was added to
the mixture, which reacts with primary amines (i.e.,
the free lysine formed as the product of the reaction)
to generate a fluorescent product with a linear
dependence on concentration.39,44,47 Under the condi-
tions of our assay, we could reliably quantify amine
concentrations of 0.2 to 100 mM (5–2500 pmol; Fig. 2).
The assay is easily adapted for either endpoint char-
acterization or generation of steady-state parameters.
Standard buffer conditions for assessing KDAC
activity against the Fluor-de-Lys substrate (50 mM
tris pH 8.0, 2.7 mM KCl, 137 mM NaCl, 1 mg mL21
BSA, 1 mM MgCl2) lack biological relevance and
more closely resemble extracellular conditions than
the cytosol.46,48 In addition, the use of an amine-
based buffer is not suitable for fluorescamine due to
the reaction of the fluorescamine with the buffer.
Therefore, we chose a buffer for our assay (30 mM
potassium phosphate pH 7.6, 100 mM KCl, 5% glyc-
erol) that was closer to physiological intracellular
conditions. While KDAC8 has been shown to be
most active between pH 8 and 9,49 we decided that
it was more appropriate to assess activity under a
more physiologically relevant pH which still retains
a reasonable degree of activity under in vivo condi-
tions. Furthermore, phosphate buffer resulted in
approximately 103 greater sensitivity than MOPS
buffer or HEPES buffer (compare Fig. 2 to Support-
ing Information Fig. S1), even though MOPS and
HEPES have tertiary amines that are not expected
to react efficiently with fluorescamine. Borate buf-
fers resulted in a slightly reduced sensitivity com-
pared with phosphate buffer and are not effective
buffers at physiologically relevant pH values (data
not shown). For these reasons, we utilized the phos-
phate reaction buffer described above in our assay,
which allowed us to use more physiological condi-
tions than previous assays, with enough enzyme
activity to maintain adequate sensitivity. Addition of
up to 3 mM MOPS (from the protein storage buffer),
5 mM nicotinamide, 100 mM SAHA, 500 mM NAD1,
and 100 mM NADH did not significantly affect the
resulting signal (data not shown).
Several other parameters were also critical to
the sensitivity and reproducibility of this assay.
First, fluorescamine was dissolved in DMSO for
detection of free amines. Although fluorescamine is
soluble in several other solvents, they were not suit-
able for this assay. Using acetone and acetonitrile
both resulted in precipitation when added to the
reaction. Furthermore, DMSO has been previously
shown to enhance the signal of fluorescamine when
present to approximately 50% in the final solution.50
Adding NaCl to the reaction at a final concentration
of 0.25 M before adding the fluorescamine prevented
precipitation of phosphate when DMSO was used as
the solvent. Removal of the enzyme by filtration
before addition of fluorescamine, as reported by
other investigators,36,44 was not necessary under our
reaction conditions and did not enhance signal
intensity.
Figure 1. Fluorescamine reaction scheme. Peptide substrates,
shown here as a 5-mer, are initially deacetylated by a KDAC.
After stopping the reaction, fluorescamine is added to generate
a fluorescent product. Fluorescamine reacts more efficiently
with primary amines than with secondary or tertiary amines, and
only the product of a reaction with a primary amine is fluores-
cent. The N-terminus and C-terminus of the peptide are acety-
lated and amidated, respectively, to better mimic the
presentation of a sequence within a longer protein sequence.
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Note that as the fluorescamine solution aged, sig-
nal intensity was lost, equivalent to an approximately
20% decrease in signal intensity after 1 month; how-
ever, sensitivity was not greatly affected, with only a
slight loss of low-end sensitivity. For this reason,
standards were included with each experiment to
accurately quantitate activity. Signal intensity was
stable from 20 min to at least 24 h after addition of
fluorescamine solution to the reaction provided the
fluorescamine solution was aged a day before use, as
suggested by prior reports.50,51 Detection of fluores-
cence several hours after addition of fluorescamine
resulted in a slight improvement (5%) of low-end
sensitivity compared with measurement 20 min after
fluorescamine addition (data not shown).
Additionally, we performed all enzymatic reac-
tions at 258C, as the enzyme does not appear to be
stable at 378C under our reaction conditions. A
direct comparison of enzymatic activity at these two
temperatures, using two peptide substrates, indi-
cated that KDAC8 lost most of its activity after 1.5
to 2 h incubation at 378C, but remained active at
258C well past that point (Supporting Information
Fig. S2). To determine whether the decrease in
activity at higher temperatures could be attributed
to protein instability, we used circular dichroism to
monitor the enzyme at both temperatures over time.
Consistent with the activity data, structural changes
were observed during the timeframe of the reaction
when the enzyme was incubated at 378C, but not at
258C (Supporting Information Fig. S3), with signifi-
cant changes in structure evident after 1 h at 378C
but not at 258C. To ensure that this effect was not
due simply to a poor choice of buffer conditions, we
also performed similar assays using a Fluor-de-Lys
substrate in the recommended buffer and observed a
similar loss of activity over time at 378C (data not
shown).
Peptides corresponding to known acetylated
proteins are deacetylated in vitro by KDAC8
Because our assay is not dependent on a fluores-
cently labeled substrate, we were able to easily
assess several potential substrates. In this way, we
were able to investigate KDAC8 activity in a more
biologically relevant manner, allowing us to address
substrate specificity. Based on previous work, mostly
utilizing mass spectrometry approaches, thousands
of acetylation sites have been identified in vivo.1–6
To begin to investigate whether any of these acetyla-
tion sites could be deacetylated by KDAC8, we
designed a limited panel of 5-mer peptides, each
from a known acetylated protein, with the sequence
ac-X-X-{K-ac}-X-X-am (Fig. 1). N-terminal acetyla-
tion and C-terminal amidation were utilized to bet-
ter mimic an internal protein sequence, so as to
avoid possible effects from N-terminal and C-
terminal charges on the peptide that would not be
found in the source protein. We began with 5-mer
peptides specifically to compare the activity with our
label-free substrates to the predictions from prior
work examining the impact of the sequence adjacent
to the acetylated lysine in a labeled substrate. Of
the peptides tested, only three had previously been
linked specifically to KDAC8: ac-IS{K-ac}FD-am, ac-
AR{K-ac}ST-am, and ac-PV{K-ac}FI-am (in the con-
text of a 9-mer).25,52 Two others (ac-YS{K-ac}GF-am
and ac-YQ{K-ac}WD-am) are from proteins known to
be deacetylated by KDAC8; however, it is either not
known which lysine within these proteins is the true
KDAC8 substrate or another acetylated lysine has
recently been identified as the likely KDAC8 sub-
strate.21,24,53 We performed the fluorescamine assay
described above with each of these peptides to deter-
mine whether KDAC8 could deacetylate any of the
potential substrates. After estimating initial reaction
rates from endpoint experiments, we found that sev-
eral of the potential substrates were deacetylated by
KDAC8 in vitro (Table I). Not surprisingly, there
was a fairly large range of activity associated with
the various peptide substrates, indicating that the
sequence immediately surrounding the acetylated
lysine is an important determinant for KDAC8 activ-
ity. As expected, circular dichroism spectra of the
peptides did not indicate any regular secondary
structure of the substrates (data not shown).
To further validate the measured activity using
our assay, we compared the endpoint activity of
KDAC8 with a 9-mer peptide (ac-STPV{K-ac}FISR-
am) as measured by our assay and a previously
reported coupled assay for acetate.36 Under our
assay conditions, KDAC8 showed lower activity than
what was previously reported for this substrate
(5.46 1.7 pmol min21 mg21 compared with a predicted
Figure 2. Sensitivity of fluorescamine assay. Several concen-
trations of unacetylated lysine (ac-K-NH2) in reaction buffer
were treated in the same manner as reactions. Error bars
represent the standard deviation of triplicate measurements.
Line represents a weighted linear fit to the data. r25 0.9998.
Inset shows the same data zoomed to only the low concen-
trations, illustrating the fit to points at both extremes.
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value of 21 pmol min21 mg21 based on the reported
kcat and KM).
25 To determine whether this difference
was due to differences in buffer and reaction tempera-
ture, we repeated our assay using a HEPES-based
buffer and increased the temperature to 308C to
mimic the conditions under which this reaction was
measured previously. Under these conditions, the
activity increased to 2465 pmol min21 mg21, which is
in agreement with the activity measured using the
coupled acetate assay, thus validating our quantifica-
tion of product formation. To confirm the apparent
buffer-specific differences in activity, we performed a
Fluor-de-Lys assay using KDAC8 and the Fluor-de-
Lys HDAC8 substrate in either our phosphate-
containing reaction buffer at 258C or the HEPES-
containing buffer at 308C. Not surprisingly, KDAC8
was more active in the HEPES-containing buffer than
the phosphate-containing buffer in this assay, 466 5
pmol min21 mg21 and 23.66 3.0 pmol min21 mg21,
respectively. Unfortunately, it is not possible to assay
the Fluor-de-Lys reaction directly using fluoresc-
amine due to interference from the intense fluores-
cence of the 7-amino-4-methylcoumarin attached to
the substrate in the 50% DMSOmixture.
Local sequence affects both binding affinity and
catalytic rate
Differences in KDAC8 activity against different sub-
strates may be due either to changes in the binding
affinity of the substrate to the active site or changes
in the rate of catalysis. A major limitation of the end-
point experiments (Table I) is that they cannot distin-
guish between these two possibilities. We used the
fluorescamine assay to perform analysis of the steady-
state kinetics on selected peptide substrates (Fig. 3
and Table II). Those peptides which showed clear
activity in the endpoint experiment and which were
sufficiently soluble in reaction buffer were character-
ized in this manner. Of the peptides subjected to this
analysis, three had KM> 2 mM. Based on experimen-
tal limitations, accurate KM values could not be
worked out for these substrates, as the substrate
could not be added to the reaction at a high enough
concentration to adequately saturate the reaction.
Furthermore, exact catalytic rates were also not able
to be determined for these substrates. The other four
substrates had weak, but measurable KM values
(ranging from 730 mM to 1.5 mM). Interestingly, we
also noticed a range of catalytic rates, ranging from
0.03 to 0.18 molecules per second. These data suggest
that the sequence surrounding the acetylated lysine
affects binding affinity and catalytic rate independ-
ently. The catalytic efficiencies ranged from a maxi-
mum of 1716 13 M21 s21 to at least 10-fold lower,
even for those peptides with sufficient activity to
obtain a reliable efficiency value, indicating that
KDAC8 has significant substrate preferences for cata-
lyzing some peptides over others. We did not observe
substrate or product inhibition effects even at very
high substrate concentrations (5 mM).
Applicability to other KDAC classes
To demonstrate the utility of our assay for a range
of KDACs other than the class I metal-dependent
Table I. Endpoint Activity for Selected Peptides with KDAC8
Peptide sequence
Activity
(pmol min21 mg21) Source protein(s) Refa
ac-FR{K-ac}RW-am 19.563.6 Arf-GAP with dual PH domain-containing
protein 1 (ADAP1)
3
ac-SL{K-ac}FG-am 12.162.4 Succinate dehydrogenase [ubiquinone]
flavoprotein subunit, mitochondrial (SDHD)
3,6
ac-IS{K-ac}FD-am 6.962.0 AT-rich interactive domain-containing
protein 1A (ARID1A)
25
ac-LT{K-ac}SP-am 5.962.8 Non-muscle caldesmon (CALD1) 5
ac-FA{K-ac}WR-am 4.562.1 Fructose-bisphosphate aldolase A (ALDOA);
Fructose-bisphosphate aldolase C (ALDOC)
3,6
ac-PV{K-ac}FI-am 3.560.7 Cysteine-rich protein 2-binding protein (CSRP2BP) 3,6
ac-YS{K-ac}GF-am 2.861.4 Src substrate cortactin (SRC) 3,6
ac-YQ{K-ac}WD-am 2.560.8 Structural maintenance of chromosomes
protein 3 (SMC3)
3,6
ac-AR{K-ac}ST-am 2.260.3 Histone H3.1t (HIST3H3); Histone H3.3 (H3F3A);
Histone H3.1 (HIST1H3A)
3,52
ac-FS{K-ac}AF-am 2.260.8 Nucleolar RNA helicase II (DDX21) 3,5,6
ac-TG{K-ac}TF-am 1.660.3 Actin-related protein 2/3 complex subunit 2 (ARPC2) 3,5
ac-VI{K-ac}GF-am 1.360.1 Transferrin receptor protein 1 (TFRC) 4
ac-LA{K-ac}HA-am 0.960.8 Histone H2B type 1-K (HIST1H2BK) 3,5,6
ac-LH{K-ac}LL-am 0.660.5 Nuclear receptor co-activator 3 (NCOA3);
Nucleoprotein TPR (TPR)
3,5,6,25
ac-SD{K-ac}TI-am None detected Tubulin alpha-3 chain (TUBA3A) 5
a Reference source that the sequence is acetylated, which usually does not coincide with a report that the sequence is a
substrate for KDAC8.
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KDAC8, we tested peptides previously reported as
substrates for class II (metal-dependent) and class
III (NAD-dependent sirtuins) enzymes (Table III)
with a representative enzyme from each of these
classes. Our measured specific activity for Sirt1 and
its substrate is slightly less than half the previously
reported value, as expected based on the low purity
of the commercially available Sirt1 we utilized (Sup-
porting Information Fig. S4) and the presence of the
GST tag compared with highly purified full-length
Figure 3. KDAC8 activity with selected peptides. KDAC8 was incubated with several concentrations of each peptide. Aliquots
were removed and stopped at various timepoints to determine the initial deacetylation rate for each reaction. For each sub-
strate, concentration was plotted against initial rate and non-linearly fit to the Michaelis-Menten equation. Steady-state kinetics
parameters (Table II) were calculated from these data. Peptide ac-YQ{K-ac}WD-am (F) was not soluble above 2 mM.
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and tag-free Sirt1.54 While each of the three enzymes
reacted in a statistically identical manner with respect
to the ARID1A peptide, their selectivity for the other two
peptides tested in this study were variable (Table III).
Notably, KDAC6 was more active with the three pep-
tides identified as KDAC8 substrates than the previ-
ously reported KDAC6 substrate.
Discussion
The assay presented here can be used to monitor
deacetylation of a variety of substrates, including
peptides or even proteins, without the need for modi-
fication of substrates, such as attachment of a fluoro-
phore. It is quantitative, and, because standards are
used, activity is expressed as an actual rate, allowing
direct comparisons between enzymes or substrates,
even when other assays were used to determine
activity. A limitation of this approach is that the sub-
strate cannot contain high levels of other free amines,
as they will also react with fluorescamine and lead to
high background signals. Under our reaction condi-
tions, with substrate:enzyme ratios of at least 300:1,
background from the enzyme was not a significant
factor even though KDAC8 contains 22 free amines
(i.e., as long as substrate was at least 10–15 more
concentrated than other amines on a molar basis).
This assay remains linear over a range of approxi-
mately three orders of magnitude and is highly sensi-
tive. A sensitivity of 0.2 mM (5 pmol) was easily
achieved when performing the assay. In contrast, other
assays using fluorescamine to detect deacetylated
lysine report much lower sensitivities (approximately
10–12 mM).44,45 A recently reported continuous,
coupled assay for metal-dependent KDACs measuring
acetate production was able to achieve 1 to 2 mM sensi-
tivity; however, that assay has the disadvantage that it
is much more complex than the assay presented here
and it is not suitable when NADH or other interfering
fluorophores are present.36 In fact, the only previously
reported assays which show comparable sensitivities
and linear range to the assay presented here involve
substrates modified with fluorescent dye, such as the
commercially available Fluor-de-Lys substrates.27 Our
assay conditions also did not show any evidence of sub-
strate or product inhibition for any of the tested pep-
tides, unlike prior reports using alternate assay
conditions,36 and we were able to quantify activity
using substantially lower enzyme concentrations than
typically reported in prior work.
Despite being at least equivalent to our assay in
terms of sensitivity and linear range, there are sev-
eral reasons why it is desirable to avoid assays uti-
lizing fluorescently conjugated substrates. Based on
previous reports that conjugating coumarin dye mol-
ecules to the substrate positively affects KDAC
activity,32,36 it is obviously advantageous to be able
to evaluate enzymatic activity in the absence of
these molecules. Additionally, while convenient for
adapting to high-throughput applications such as
screening for small molecules which affect KDAC
activity, fluorescently labeled substrates are not
well-suited for other studies. They require more
involved synthesis than unlabeled substrates, mak-
ing them less suitable for applications where several
Table II. Steady-State Kinetics Parameters for Peptides with KDAC8
Peptide sequence kcat (s
21) KM (mM) kcat/KM (M
21 s21) Source protein(s)
ac-FR{K-ac}RW-am 0.1626 0.007 9506 110 1716 13 ADAP1
ac-SL{K-ac}FG-am 0.1786 0.006 15006 120 1186 6 SDHD
ac-IS{K-ac}FD-am 0.0516 0.002 7506 80 696 4 ARID1A
ac-LT{K-ac}SP-am >0.10 >2000 32.16 0.8 CALD1
ac-FA{K-ac}WR-am 0.0376 0.004 7306 170 516 8 ALDOA; ALDOC
ac-YQ{K-ac}WD-am >0.03 > 2000 17.46 1.0 SMC3
ac-AR{K-ac}ST-am >0.03 > 2000 16.36 1.1 HIST3H3; H3F3A;
HIST1H3A
Table III. Endpoint Activity for Selected Peptides with Sirt1 and KDAC6
Activity (pmol min21 mg21)
Peptide sequence Sirt1 KDAC6 KDAC8d Source protein
ac-QLS{K-ac}WP-am 21.26 2.9a —b —b FOXO3
ac-DGQMPSD{K-ac}TIGGGD-am —b 1.26 0.2c —b TUBA3A
ac-FR{K-ac}RW-am 386 6 166 6 19.56 3.6 ADAP1
ac-SL{K-ac}FG-am 18.66 1.4 4.36 0.8 12.16 2.4 SDHD
ac-IS{K-ac}FD-am 7.36 0.4 7.26 2.2 6.96 2.0 ARID1A
a Predicted activity calculated from previously reported kcat and KM in the sirtuin coupled assay is 50.06 2.5
pmol min21 mg21.54
b Not reported.
c Previously reported as a substrate but not characterized with absolute rate.59
d Data from Table II repeated for comparison.
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substrates are being queried. Also, the presence of the
conjugated dye limits the ability to study the sequence
surrounding the lysine, making these substrates less
amenable for studies of substrate specificity. In
contrast, our approach has increased versatility and
better represents biological substrates compared
with labeled substrates while retaining comparable
sensitivity.
The fluorescamine method is inexpensive com-
pared with coupled assays involving multiple addi-
tional enzymes, and can be used with all lysine
deacetylases. As our method relies solely on detection
of lysine, it should also be usable for other lysine-
modifying enzymes and the removal of functional
groups other than acetate. However, these advantages
do come with one significant limitation: the need to
minimize the presence of other primary amines in the
reaction. This limitation has two practical effects.
First, the N-terminus of the substrate should be
“capped,” such as by an acetyl group. This limitation
will typically only be of minor concern, as acetylating
the N-terminus also removes the positive charge of the
N-terminus and therefore better mimics most internal
protein sequences. Therefore, this limitation is only
significant for peptides that include the true N-
terminal sequence from the source protein. The second
limitation is that the substrate cannot contain any
other unmodified lysine residues without dramatically
increasing the background signal. Note that the pres-
ence of arginine or modified lysine residues is not a
concern. For a sufficiently active substrate, the pres-
ence of one additional lysine would not necessarily pre-
clude measurement of the activity, but the sensitivity
would drop at least an order of magnitude (comparable
to changing from a phosphate buffer to MOPS or
HEPES). Additional lysine residues would further
reduce the sensitivity. As is true for all deacetylation
assays, if multiple acetylated lysine residues are pres-
ent and simultaneously deacetylated by a KDAC, the
interpretation of activity may be more complex. As a
significant number (but by no means a majority) of
reported acetylated lysine residues include a second
lysine residue nearby,1–6 our assay is not the best
choice to screen every known acetylated sequence.
However, fluorescamine would be appropriate as a first
approach to screen a majority of potential substrates
with as many enzymes as possible and to take advant-
age of its high sensitivity. As the activity measure-
ments are consistent with other assays, coupled assays
could then be used for the sequences not easily meas-
ured by fluorescamine, thereby substantially reducing
overall costs and increasing throughput compared
with utilizing coupled assays for all sequences.
Previous attempts to address substrate specificity
of KDAC8 have been conducted using panels of peptide
substrates that are either conjugated to a fluorophore
or are attached at one end to a solid surface.30,31 Using
these methods, the effect of residues in the positions
either directly upstream (22, 21) or directly down-
stream (11, 12) on substrate specificity was analyzed
independently. Using the techniques presented in
those reports, it was not possible to simultaneously
address the residues on either side of the lysine. A
major advantage of the assay presented here is that it
was possible to simultaneously investigate the effects
of residues on either side of the acetylated lysine on
substrate preference. We compared the normalized
activity of the residues in these assays to the normal-
ized activity of the peptides studied in our assay (Fig.
4). Surprisingly, the activity of KDAC8 against the pep-
tides used in this study did not correlate to the predic-
tions from either of the previous studies we analyzed
in this way. In particular, we did not observe the strong
bias toward aromatic residues in the 11 position that
has been previously reported,31 although our substrate
sequence diversity is too great to draw specific conclu-
sions regarding substrate specificity using our limited
sample size. Thus, the previously performed screens to
address substrate specificity cannot accurately predict
activity in a more physiological context. These discrep-
ancies highlight the importance of using more biologi-
cally relevant substrates and assay conditions, as the
context in which the acetylated lysine is presented to
the enzyme affects the substrate preference. To com-
pare activity in our assay to activity obtained in these
previous studies without adding additional complexity,
we focused on 5-mer peptides lacking regular second-
ary structure in this study. Future investigations will
be needed to further explore how amino acids more dis-
tant from the acetylated lysine and/or secondary struc-
ture affects KDAC activity. As described in a recent
review of KDAC8 substrates, the low catalytic effi-
ciency with the tested substrates, compared with typi-
cal values of 105 to 106 M21 s21, suggests that either
better substrates exist but have yet to be identified or
that the enzyme requires an unidentified cofactor or
participation in a multiprotein complex for maximal
activity.22
Interestingly, one of the peptides with which
KDAC8 showed the highest activity in our assay
(ac-IS{K-ac}FD-am) corresponds to ARID1A, a tumor
suppressor which was previously identified as a
KDAC8 substrate in cells and confirmed in vitro.25 We
obtained a kcat/KM value that was approximately 10-
fold less than the value previously reported; however,
our value was determined with the 5-mer peptide and
the previously reported value was determined with the
9-mer. Our KM value for the 5-mer peptide is approxi-
mately two-fold lower than the value obtained using
the 9-mer peptide in the previous study.25 This differ-
ence in KM values for the 5-mer and 9-mer peptide sug-
gests that the additional amino acids significantly
influence the activity; however, the majority of the
reduction is presumably due to a reduced catalytic
activity with the 5-mer peptide compared with the 9-
mer, which can largely or entirely be attributed to the
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greater activity of KDAC8 in the previously reported
HEPES-containing buffer. The CSRP2BP 9-mer also
exhibited higher endpoint activity than the corre-
sponding 5-mer, suggesting that the effect of peptide
length and residues more remote from the acetylated
lysine should be a focus for future studies. However,
our measured catalytic efficiencies are near those
reported for several potential substrates identified by a
pull-down assay.25 The KM values determined for the
KDAC8 substrates are also within the range of previ-
ous reports, which are usually reported as in excess of
1 mM and often only reported as a lower limit.9,25,36,49
As described previously, our assays were all conducted
at 258C in phosphate buffer at pH 7.6, which is similar
to conditions used for the previously reported coupled
sirtuin assay.37,38 In contrast, the prior characteriza-
tion of KDAC8 substrates was conducted in HEPES
pH 8.0 and 308C, which is closer to the pH and temper-
ature optimum for the enzyme but less physiologically
relevant. The change in reaction conditions to our
phosphate buffer does result in a decreased rate. How-
ever, our phosphate buffer is a better mimic of intracel-
lular conditions (pH <8, high potassium, low sodium)
than previously reported buffers.48,55 In addition, the
use of a phosphate buffer, with a pKa substantially
lower than amine-type buffers, means that the reaction
buffer pH could be lowered to reflect the conditions in
different intracellular organelles down to a pH of
approximately 6 and therefore cover almost the entire
range of relevant intracellular pH values.56
Peptides from the other previously identified
KDAC8 substrates tested in our experiments [His-
tone 3 lysine9 (H3K9), cortactin, and structural
maintenance of chromosomes protein 3 (SMC3)]
were also deacetylated by KDAC8 in our assay,
albeit with a lower activity than the ARID1A
peptide. These substrates were identified from cell
lysate experiments in which the acetylation status of
these proteins were affected by changes in KDAC8
expression in cells.21,24,52,53 As the previous studies
did not directly test activity of KDAC8 against these
substrates in vitro, this study represents the first
evidence that these sequences are substrates for
KDAC8 and that the observed in vivo effects are due
to direct deacetylation by KDAC8 rather than indi-
rect effects. These results demonstrate that the
assay developed here will be a powerful complemen-
tary approach to confirm deacetylation targets iden-
tified using cell-based approaches for any lysine
deacetylase. By combining results from our assay
with mass spectrometry-based experiments and cell-
based experiments as done for the examples above,
we can begin to truly identify specific KDAC-
substrate pairs and understand the biological conse-
quences of these interactions.
The assay presented here is an excellent tool for
understanding KDAC substrate specificity. It is rela-
tively simple compared with other reported deacety-
lase assays. Additionally, it is very sensitive and is
linear over a wide range. This assay is particularly
amenable for probing substrate specificity, as sub-
strates do not require any special modification, such
as a fluorophore, and the assay is designed to be
easily conducted in 96-well format, allowing multiple
potential substrates to be assayed simultaneously.
These advantages are critical for identifying sub-
strates for individual KDACs, which will facilitate a
major long-term goal of the field to translate the
substrate identification into greater understanding
of the biological pathways regulated by KDACs. The
best substrates identified here are near the activity
for the best labeled substrate available for KDAC8
(compare Table I with 23.663.0 pmol min21 mg21
for the Fluor-de-Lys HDAC8 substrate), and so our
method could serve as replacement tool for screening
for inhibitors using a more biologically relevant
Figure 4. Screens with labeled substrates do not reflect activity in the fluorescamine assay. Normalized activity of endpoint assays
(Table I) does not correlate with (A) a screen of all possible22 and21 sequences using fluorophore-labeled peptides (r250.18)31
or (B) a screen of all possible11 and12 sequences using surface-attached peptides (r250.02).30 Lines represent a hypothetical
perfect correlation; deviation from the line indicates disagreement between observed and predicted results. Error bars come from
experimental results (x-axis) or are extrapolated based on the reported precision of values used for predictions (y-axis).
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substrate and at substantially reduced cost compared
with screens against labeled substrates. Furthermore,
the techniques presented here could potentially be
used to investigate nonacetyl modifications that may
be removed by KDACs, as has recently been
suggested.13
Materials and Methods
KDAC8 expression and purification
pJExpress401 vector (DNA 2.0) containing codon-
optimized human KDAC8, fused to a tobacco-etch
virus (TEV) protease cleavage site and His6 tag
(pJExpress-KDAC8), was used to express KDAC8 in
BL21 Escherichia coli. Cells were grown in 23 YT
broth at 378C with shaking at 250 rpm. When cells
reached an OD60050.8–1.0, 50 mM ZnCl2 and 1 mM
IPTG were added, followed by an additional 3.5 h of
growth at 378C. After induction, cells were harvested
by centrifugation at 3500 rpm for 20 min at 48C.
Cells pellets were stored at 2208C until lysis.
Cells were resuspended in lysis buffer (30 mM
MOPS pH 8.0, 150 mM KCl, 5% glycerol, 5 mM
imidazole, 2 mM MgCl2, 13 HALT protease inhibitor
[Thermo Scientific], 0.5 mg mL21 egg white lyso-
zyme) and incubated with rocking for 30 min on ice
(typically 10 mL of lysis buffer was used per 1 L
cells harvested). Cell suspensions were sonicated
three times at 30% amplitude for 10 sec (Fisher Sci-
entific Sonic Dismembrator Model 120, 1/8” probe),
followed by 30 sec on ice. Lysates were clarified by
centrifugation at 27,000g for 20 min at 48C.
Clarified lysate was added to TALON resin (Clon-
tech) equilibrated with column buffer (30 mM MOPS
pH 8.0, 150 mM KCl, 5% glycerol, 5 mM imidazole)
and incubated on ice for 15 min with rocking (resin
bed volume of 1 mL per 10 mL lysis buffer). Resin was
pelleted by centrifugation at 700g for 5 min and
washed twice with 10 bed volumes of column buffer
each time. After final centrifugation, resin was trans-
ferred to column housing and washed with an addi-
tional 10 bed volumes of column buffer. KDAC8 was
eluted (30 mM MOPS pH 8.0, 150 mM KCl, 5% glyc-
erol, 150 mM imidazole) and collected in fractions.
TEV protease was added (1:25) to fractions containing
protein, and the mixture was dialyzed in TEV cleav-
age buffer (30 mM MOPS pH 8.0, 150 mM KCl, 5%
glycerol, 1 mM 2-mercaptoethanol, 0.3 mM EDTA pH
7.0) overnight at 48C with one buffer change. This was
followed by dialysis into buffer containing 30 mM
MOPS pH 8.0, 150 mM KCl, and 5% glycerol over-
night at 48C with one buffer change.
Following cleavage with TEV protease, protein
was flowed over TALON resin equilibrated with the
final dialysis buffer for secondary purification. Purified
KDAC8 (flow-through) was collected. Glycerol and
tris(2-carboxyethyl)phosphine (TCEP) were added to
final concentrations of 25% and 1 mM, respectively.
ZnCl2 was added to an equimolar ratio to KDAC8 and
protein was stored at 2208C. Using this storage
method, KDAC8 activity was stable for at least several
months. This protocol typically yielded approximately
1 mg KDAC8 per liter of culture, at a purity of >95%
(assessed by SDS-PAGE and stained with GelCode
Blue (Thermo Scientific); Supporting Information
Fig. S5).
TEV protease expression and purification
His6-tagged TEV protease was expressed and puri-
fied from E. coli transformed with pRK793 (Add-
Gene 8827) using metal affinity chromatography.57
Briefly, cells were grown in 23 YT broth at 378C
with shaking at 250 rpm until OD600 reached
approximately 1.0 and then induced with 1 mM
IPTG. After 4 h, cells were harvested and TEV pro-
tease was purified using TALON resin, similarly to
the protocol above for KDAC8. The protein of inter-
est was eluted (30 mM MOPS pH 8.0, 150 mM KCl,
5% glycerol, 150 mM imidazole) and fractions con-
taining protein were dialyzed into storage buffer
(30 mM MOPS pH 8.0, 150 mM KCl, 25% glycerol,
1 mM TCEP) and stored at 2208C.
Fluorescamine assay
Peptides were custom synthesized with acetylated
lysine in the middle position, as well as an acety-
lated N-terminus and an amidated C-terminus (Gen-
script). All peptide masses were confirmed by mass
spectrometry, purified to >95% by HPLC, and stored
as concentrated stocks in buffer or DMSO as deter-
mined by solubility. For endpoint assays, 100 mM
peptide substrates were incubated with 200 nM
KDAC8, 200 nM human Sirtiun1(193-741)-GST
(Sirt1, BPS Bioscience), or 20 nM human HDAC6-
GST (KDAC6, BPS Bioscience) at 258C for 60 min in
reaction buffer (30 mM potassium phosphate pH 7.6,
100 mM KCl, 5% glycerol) or HEPES reaction buffer
(50 mM HEPES pH 8.0, 137 mM NaCl, 2.7 mM KCl)
in a reaction volume of 90 mL. Reactions with Sirt1
also included 500 mM NAD1. Reactions were stopped
by addition of suberoylanilide hydroxamic acid
(SAHA) to a concentration of 100 mM for metal-
dependent KDACs or 5 mM nicotinamide for Sirt1.
For each reaction, an identical inhibited reaction
was prepared which contained 100 mM SAHA or
5 mM nicotinamide preincubated with enzyme
before addition of substrate. Additional enzyme-only
and substrate-only controls were also subjected to
the same reaction conditions to verify the effective-
ness of the inhibitor. The reaction mixture was
diluted 1:1 with 0.5 M NaCl and 50 mL aliquots were
added to black polypropylene 96-well plates (Corn-
ing) in triplicate. 50 mL of 0.1 mg mL21 fluoresc-
amine in spectroscopic grade DMSO was then added
to each well. Plates were incubated at room temper-
ature for at least 20 min. Fluorescence was detected
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in a microplate reader (BioTek) at 390 nm excitation
and 485 nm emission.39
To create a standard curve, several concentra-
tions (ranging from 100 mM to 0.16 mM; 2500–4 pmol
per well) of unacetylated lysine (N-a-acetyl-L-lysine
amide hydrochloride, ac-Lys-NH2; Chem-Impex
International) were prepared and incubated in the
same manner as reactions, the fluorescence was
measured, and pmol versus fluorescence was line-
arly fit. For each reaction, the initial rate (V0) was
calculated by subtracting the average raw fluores-
cence of the inhibited reaction from the average raw
fluorescence of the reaction. This number was
divided by the slope of the standard curve and cor-
rected for NaCl dilution and to scale from the vol-
ume of a single well to the total reaction volume.
The resulting pmol were then divided by the reac-
tion time and enzyme concentration to report spe-
cific activity, which allowed for direct comparison
between experiments. Specific activity values were
averaged for at least three reactions with each pep-
tide. Statistical outliers, calculated using the Grubbs
method,58 were tested for and excluded when
detected in any data sets of at least four independ-
ent measurements.
Fluor-de-Lys assay
Assays were performed identically to the fluoresc-
amine assay except for the following changes. The
substrate used was the Fluor-de-Lys HDAC8 sub-
strate (Enzo Life Sciences), which has the sequence
ac-RH{K-ac}{K-ac}-7-amino-4-methylcoumarin.
Assays were performed in either reaction buffer or
HEPES reaction buffer. After stopping the reactions,
2 mg mL21 trypsin (MP Biomedical) in reaction
buffer was added instead of 0.5 M NaCl, and the
mixtures were incubated at 378C for 15 min. The
mixtures were then added in triplicate to the 96-
well plate and fluorescence measured with excitation
at 360 nm and emission at 460 nm. Fluorescence
was converted to rates using a standard curve of 7-
amino-4-methylcoumarin (Alfa Aesar).
Fluorescamine steady-state kinetics assay
conditions
Fifteen concentrations of peptide substrates were
incubated with 150 nM KDAC8 in reaction buffer at
258C. Aliquots were taken from the reactions at sev-
eral timepoints (0, 10, 20, 40, 60 min), and the reac-
tions were stopped by addition of SAHA to 100 mM.
Aliquots continued to incubate at 258C until the
final timepoint. Each aliquot was processed as
described above for stopped reactions. A standard
curve was also generated for each experiment as
described above.
For each reaction, the slope resulting from fluo-
rescence versus time was obtained. These slopes
were converted to the rate of substrate conversion
(pmol min21) by dividing by the slope of the stand-
ard curve. Rates for each substrate concentration
were plotted, and Michaelis-Menten steady-state
parameters were calculated using QTIplot software
by nonlinearly fitting the Michaelis-Menten equa-
tion. Catalytic efficiency was calculated directly
from velocity data using a derivative of the Briggs-
Haldane equation as described elsewhere,36 even for
substrates for which KM and kcat could not be reli-
ably determined individually.
Temperature stability assays
A steady-state kinetics fluorescamine assay was per-
formed as described above with a few modifications
to address enzyme stability at higher temperature.
200 mM of each peptide substrate or Fluor-de-Lys
reagent (Enzo Life Sciences) was incubated with 125
nM KDAC8 in reaction buffer at either 258C or
378C. Aliquots of each reaction were stopped at 0,
0.5, 1, 1.5, 2, 2.5, and 3 h and worked up as
described above for the corresponding assay. Stabil-
ity was also monitored by CD spectrophotometry
using a J-1500 spectrapolarimeter (Jasco). 500 nM
KDAC8 in reaction buffer was incubated at either
258C or 378C. Spectra were obtained from 200 to
245 nm at a scan rate of 5 nm min21 with a 16 s
integration every 1.0 nm in a 2 mm quartz cuvette
with a 1.0 nm bandwidth. One buffer-corrected spec-
trum was taken every 10 min for 3 h at each
temperature.
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Figure S1. MOPS and HEPES buffers result in loss of sensitivity. Several concentrations of unacetylated lysine (ac-K-NH2) in MOPS buffer (30 mM MOPS pH 8.0, 150 mM KCl, 5% glycerol; A) or HEPES buffer (50 mM HEPES pH 8.0, 137 mM NaCl, 2.7 mM KCl; B) were treated in the same manner as reactions. Error bars represent the standard deviation of triplicate measurements. Line represents a weighted linear fit to the data. r2  = 0.9969 (MOPS) and 0.9998 (HEPES). Insets show the same data zoomed to only the low concentrations. At least 2 µM standard is required to obtain a signal above background, and the maximum signal intensity is far lower than in the phosphate buffer (Figure 2).
Figure S2. KDAC8 activity at 25 °C versus 37 °C. KDAC8 was incubated with ac-SL{K-ac}FG-am (A) or ac-FA{K-ac}WR-am (B) at either 25 °C (black squares) or 37 °C (gray circles). Aliquots were taken at indicated timepoints and processed as described in the materials and methods. Fluorescence, corresponding to deacetylation, was recorded at eachtimepoint. At 37 °C, KDAC8 exhibited significant loss of activity after ~1 hr and very little activity after ~1.5 hr; however, the enzyme remained active at 25 °C for the duration of the experiment. Lines represent theoretical fits to emphasize the change in activity over time, illustrating that although the 37 °C reactions begin at faster rates, by 1 hr the total product formation is similar at the two temperatures as indicated by the intersection of the lines. The 37 °C reactions have nearly ceased after 2 hours, as illustrated by the nearly horizontal lines (gray) between 2 and 3 hours and the continued increase in product formation by the 25 °C reactions (black).
Figure S3. KDAC8 stability at 25 °C versus 37 °C. KDAC8 was incubated in reaction buffer and monitored by circular dichroism spectroscopy as described in materials and methods. (A) Comparison of 25 °C (squares) and 37 °C (circles) for initial measurement (shaded) or after 3 hr (open). The 37 °C sample exhibits significantly more change during the 3 hrs, indicated most prominently by the reduction of signal intensity around 222 nm but also accompanied by some changes in the overall spectrum. (B) The same samples monitored at 222 nm (average of 221-223 nm data points) every 10 minutes at 25 °C (black squares) or 37 °C (gray circles). By 1 hr, the 37 °C sample exhibited a significant decrease in signal intensity, consistent with the loss of activity (Figure S2). At 3 hr, the 25 °C sample has changed little whereas the 37 °C sample has continuously lost signal, indicating ongoing structural effects throughout the experiment.  
Figure S4. Purity of commercial KDACs. Approximately 2 µg Sirtuin1 (193-741)-GST (lane 2) and HDAC6-GST (lane 3) were subjected to SDS-PAGE and stained with GelCode Blue. The expected mass of the proteins are 87.2 kDa and 159 kDa, respectively. Under the staining conditions, all bands of at least 10 ng are visible. The proteins are substantially lesspure than our preparation of KDAC8, consistent with the company estimates of 60-80%.
Figure S5. Purified KDAC8. 2 µg KDAC8 purified as described in materials and methods was subjected to SDS-PAGE and stained with GelCode Blue. The expected mass of the protein is 42.5 kDa following cleavage with TEV protease. Under the staining conditions, all bands of at least 10 ng would appear. Resulting protein was ≥95% pure and used for all subsequent activity assays.
